Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Want to see IN:BAFNAPH full AI Analyst Report?
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹72.25 - ₹204.95
Previous CloseN/A
Volume2.58K
Average Volume (3M)1.19K
Market Cap
₹3.66B
Enterprise Value₹3.44B
Total Cash (Recent Filing)₹19.67M
Total Debt (Recent Filing)₹324.03M
Price to Earnings (P/E)34.2
Beta0.64
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.70
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-channel Finished-dosage ManufacturingThe company manufactures finished-dosage generics across multiple therapeutic categories and sells domestically and internationally. That diversified product and market footprint supports stable demand, export revenue, and resilience to single-market shocks over the coming months.
Sustained Multi-year Revenue GrowthReported multi-year revenue growth demonstrates the firm's ability to scale sales and retain or win customers over time. A growing revenue base helps absorb fixed costs, supports investment in manufacturing capacity, and underpins medium-term operational stability if margins are managed.
Reasonable Balance Sheet With Building EquityEquity has been building and leverage is moderate, providing a capital buffer and borrowing capacity for working capital or targeted investment. A meaningful equity base enhances resilience to cyclical pressures and supports access to financing over the next several quarters.
Bears Say
Negative And Inconsistent Free Cash FlowFree cash flow has been negative in most years, reflecting reinvestment and working-capital strain. Persistent negative FCF reduces liquidity and financial flexibility, forces reliance on external funding, and constrains organic capex, dividends, or buffer against shocks over the medium term.
Volatile Margins And Uneven Earnings QualityMargins and net income have swung materially year-to-year, indicating earnings volatility driven by pricing, mix or cost pressures. This inconsistency weakens predictability of cash generation and increases operational risk when planning investment or financing across coming quarters.
Rising Debt Trend To MonitorDebt has risen recently, which combined with weak cash conversion raises refinancing and interest-service risk. Increasing leverage can limit strategic flexibility and amplify downside if margins compress or revenue growth slows, making debt trends a durable risk to watch.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹72.25 and its highest was ₹204.95 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹3.66B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is Aug 07, 2026 which is in 62 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on May 29, 2026. The company reported ₹1.16 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.16.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹1.16 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.372%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Krebs Biochemicals & Industries Ltd.
―
Mangalam Drugs & Organics Ltd.
―